The Inherited p53 Mutation in the Brazilian Population.
A common criticism of studying rare diseases is the often-limited relevance of the findings to human health. Here, we review ∼15 years of research into an unusual germline TP53 mutation (p.R337H) that began with its detection in children with adrenocortical carcinoma (ACC), a remarkably rare childhood cancer that is associated with poor prognosis. We have come to learn that the p.R337H mutation exists at a very high frequency in Southern and Southeastern Brazil, occurring in one of 375 individuals within a total population of ∼100 million. Moreover, it has been determined that carriers of this founder mutation display variable tumor susceptibility, ranging from isolated cases of pediatric ACC to Li-Fraumeni or Li-Fraumeni-like (LFL) syndromes, thus representing a significant medical issue for this country. Studying the biochemical and molecular consequences of this mutation on p53 tumor-suppressor activity, as well as the putative additional genetic alterations that cooperate with this mutation, is advancing our understanding of how p53 functions in tumor suppression in general. These studies, which originated with a rare childhood tumor, are providing important information for guiding genetic counselors and physicians in treating their patients and are already providing clinical benefit.
Department of Oncogenetics, A.C. Camargo Cancer Center, São Paulo, SP, Brasil.
Maria Isabel
MI
Achatz
Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105.
Gerard P
GP
Zambetti
D018268:Adrenocortical Carcinoma / Q000235:genetics*; D001938:Brazil; D002648:Child; D020022:Genetic Predisposition to Disease; D018095:Germ-Line Mutation; D006801:Humans; D016864:Li-Fraumeni Syndrome / Q000235:genetics*; D010375:Pedigree; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53
PLoS One. 2014 Jun 17;9(6):e99893
24936644
Cancer Res. 2003 Oct 15;63(20):6643-50
14583457
Fam Cancer. 2009;8(4):383-90
19468865
Hum Mutat. 2010 Feb;31(2):143-50
19877175
J Cell Physiol. 2007 Nov;213(2):370-3
17671971
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9330-5
11481490
Mol Cell Endocrinol. 2012 Mar 31;351(1):37-43
22040600
J Mol Biol. 2003 Mar 28;327(3):699-709
12634062
Carcinogenesis. 2014 Apr;35(4):807-15
24336192
Cancer Res. 1994 Mar 1;54(5):1298-304
8118819
J Med Genet. 2009 Nov;46(11):766-72
19542078
Nat Commun. 2015 Mar 06;6:6302
25743702
Nat Struct Biol. 2002 Jan;9(1):12-6
11753428
J Med Genet. 2006 Jan;43(1):91-6
16033918
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4174-9
10760284
Am J Pathol. 1997 Jan;150(1):1-13
9006316
Cancer Res. 2006 May 15;66(10):5056-62
16707427
Arq Bras Endocrinol Metabol. 2004 Oct;48(5):647-50
15761534
Br J Cancer. 2000 Jun;82(12):1932-7
10864200
Ann N Y Acad Sci. 2003 May;995:59-72
12814939
J Clin Endocrinol Metab. 2012 Mar;97(3):E476-85
22170717
J Clin Oncol. 2013 Jul 10;31(20):2619-26
23733769
Oncogene. 2005 Oct 20;24(46):6976-81
16007150
Cancer Lett. 2007 Jan 8;245(1-2):96-102
16494995
Cancer Epidemiol. 2015 Apr;39(2):166-9
25736369
Cancer Lett. 2008 Mar 8;261(1):21-5
18248785
J Med Genet. 2001 Jan;38(1):43-7
11332399
Cancer Res. 1988 Sep 15;48(18):5358-62
3409256
Hum Mutat. 2007 Jun;28(6):622-9
17311302